Tesamorelin 10mg – PharmaTech

Tesamorelin is a synthetic, stabilized analogue of human growth hormone–releasing hormone (GHRH), designed to activate the growth hormone–releasing factor receptor and stimulate endogenous pulsatile growth hormone secretion.

The molecule is based on the 44-amino-acid sequence of human GHRH with an N-terminal hexenoyl modification that increases molecular stability. Tesamorelin has been extensively investigated in growth hormone physiology, body-composition research, visceral adipose tissue biology, metabolic regulation, and endocrine signaling.

OVERVIEW

Tesamorelin is a synthetic, stabilized analogue of human growth hormone–releasing hormone (GHRH), designed to activate the growth hormone–releasing factor receptor and stimulate endogenous pulsatile growth hormone secretion.

The molecule is based on the 44-amino-acid sequence of human GHRH with an N-terminal hexenoyl modification that increases molecular stability. Tesamorelin has been extensively investigated in growth hormone physiology, body-composition research, visceral adipose tissue biology, metabolic regulation, and endocrine signaling.


MECHANISM OF ACTION

Tesamorelin acts primarily as an agonist of the growth hormone–releasing hormone receptor (GHRHR) located on pituitary somatotroph cells.

Receptor activation stimulates intracellular signaling that promotes the synthesis and pulsatile secretion of endogenous growth hormone (GH). Increased GH signaling subsequently influences hepatic and peripheral production of insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 (IGFBP-3).

Primary Signaling Axis

Tesamorelin → GHRHR → GH secretion → IGF-1 / IGFBP-3 → metabolic and tissue-level effects

The physiological effects associated with this pathway include modulation of lipid metabolism, adipocyte biology, protein metabolism, and other processes regulated by the GH/IGF-1 axis.


KEY BENEFITS

Growth Hormone Axis Research

  • Activation of endogenous GHRH/GH signaling
  • Investigation of pulsatile GH secretion
  • Modulation of IGF-1 and IGFBP-3
  • Endocrine regulation research

Metabolic Research

  • Visceral adipose tissue biology
  • Lipid metabolism
  • Adipocyte function
  • Glucose and insulin metabolism
  • Energy-balance research

Body Composition Research

  • Investigation of abdominal visceral fat
  • GH-dependent changes in body composition
  • Adipose tissue remodeling
  • Lean and fat mass research

Cellular & Molecular Research

  • GHRHR-mediated signaling
  • GH-responsive cellular pathways
  • IGF-1 signaling
  • Hormonal regulation of metabolism

RESEARCH AREAS

Tesamorelin is investigated across several interconnected areas of molecular and physiological research:

Research Area Focus
Growth Hormone Biology GHRH receptor activation and endogenous GH secretion
Endocrinology GH/IGF-1 axis regulation
Metabolic Research Lipid, glucose and energy metabolism
Adipose Biology Visceral adipose tissue and adipocyte signaling
Body Composition Changes in visceral fat and lean tissue
Neuroendocrine Research Hypothalamic-pituitary signaling
Molecular Pharmacology GHRHR-mediated intracellular pathways
Clinical Research Metabolic and body-composition outcomes

SCIENTIFIC EVIDENCE

Tesamorelin has a comparatively well-characterized pharmacological profile among GHRH analogues. Clinical development demonstrated that GHRHR stimulation increases endogenous GH secretion and subsequently raises circulating IGF-1 and IGFBP-3 concentrations.

Clinical research has particularly investigated tesamorelin in the context of excess visceral abdominal adipose tissue associated with HIV-related lipodystrophy, where the compound demonstrated effects on visceral adipose tissue and body composition.

The broader research significance of tesamorelin derives from its ability to stimulate the body’s endogenous GH axis rather than directly supplying exogenous GH.


MOLECULAR PROFILE

Parameter Specification
Compound Name Tesamorelin
Synonyms TH9507, Growth Hormone-Releasing Factor Analogue
Molecular Class Synthetic GHRH analogue
Peptide Length 44 amino acids
Molecular Formula C₂₂₁H₃₆₆N₇₂O₆₇S
Molecular Weight ~5,136 g/mol
CAS Number 218949-48-5
Primary Target Growth Hormone-Releasing Hormone Receptor (GHRHR)
Structural Modification N-terminal hexenoyl modification
Physical Form Lyophilized peptide

The molecular composition and sequence are consistent with the stabilized synthetic analogue of human GHRH described in regulatory and chemical characterization records.

Peptide Sequence

Y-A-D-A-I-F-T-N-S-Y-R-K-V-L-G-Q-L-S-A-R-K-L-L-Q-D-I-M-S-R-Q-Q-G-E-S-N-Q-E-R-G-A-R-A-R-L

The N-terminal region contains the characteristic chemical modification used to generate the stabilized tesamorelin molecule.


PHARMACOKINETIC & PHARMACODYNAMIC PROFILE

Pharmacodynamic Profile

Tesamorelin stimulates endogenous GH secretion through activation of GHRHR.

Pharmacodynamic studies demonstrate subsequent increases in:

  • Growth hormone
  • IGF-1
  • IGFBP-3

The effect occurs through stimulation of the physiological GH axis rather than direct administration of growth hormone.

Pharmacokinetic Profile

Tesamorelin displays rapid absorption following subcutaneous administration.

For the currently characterized EGRIFTA WR formulation, the median Tmax is approximately 0.15 hours, while the reported mean elimination half-life following a single subcutaneous administration is approximately 11 minutes in healthy subjects. Earlier tesamorelin formulations reported half-lives of approximately 26–38 minutes depending on the population studied. DailyMed

Parameter Reported Profile
Administration Studied Subcutaneous
Tmax ~0.15 h
Elimination Half-Life ~11 min in current WR formulation
Primary Target GHRHR
Primary Pharmacodynamic Effect Increased endogenous GH secretion
Downstream Biomarkers IGF-1 and IGFBP-3

RESEARCH HIGHLIGHTS

GHRHR Activation

Tesamorelin directly stimulates the human growth hormone–releasing factor receptor with pharmacological activity comparable to endogenous GHRH.

GH/IGF-1 Axis

Activation of GHRHR increases endogenous GH secretion and subsequently modulates IGF-1 and IGFBP-3 concentrations.

Visceral Adipose Research

Tesamorelin has been extensively studied in relation to visceral abdominal adipose tissue and body-composition regulation.

Metabolic Biology

The GH/IGF-1 pathway activated by tesamorelin interacts with lipid and glucose metabolism, making the molecule relevant to metabolic and endocrine research.

Molecular Stability

The N-terminal hexenoyl modification differentiates tesamorelin from native GHRH and was incorporated to improve molecular stability.


TECHNICAL SPECIFICATIONS

Specification PharmaTech Standard
Product Name Tesamorelin
Molecular Formula C₂₂₁H₃₆₆N₇₂O₆₇S
Molecular Weight ~5,136 g/mol
CAS 218949-48-5
Peptide Length 44 amino acids
Appearance White to off-white lyophilized powder
Identity Testing Mass Spectrometry
Purity Testing HPLC
Sequence Verification MS/MS / analytical characterization
Packaging PharmaTech specification
Lot Number PharmaTech lot-specific
Certificate of Analysis Available by lot

STORAGE & HANDLING

Tesamorelin should be maintained as a lyophilized peptide under controlled storage conditions and protected from:

  • Excessive heat
  • Moisture
  • Direct light
  • Repeated temperature fluctuations

PharmaTech lot-specific storage and handling specifications should be followed according to the corresponding product documentation and Certificate of Analysis.